Okamura K, Suzuki M, Chihara T, Fujiwara A, Fukuda T, Goto S, Ichinohe K, Jimi S, Kasamatsu T, Kawai N
Cancer. 1986 Aug 15;58(4):865-72. doi: 10.1002/1097-0142(19860815)58:4<865::aid-cncr2820580411>3.0.co;2-s.
To evaluate the clinical effects of the anti-tumor polysaccharide Schizophyllan (SPG), a randomized study was done on 220 patients with Stage II or Stage III cervical cancer who had been given irradiation, concomitantly. The tumor-reducing effect of SPG was significant in patients in either stage. The time to recurrence was longer in SPG-dosed patients with Stage II cancer, compared with findings in the control group. There was no significant difference in the time to recurrence in patients with Stage III cancer between the SPG and control groups. When comparing the 48-month survival curve, the survival time of patients with Stage II cancer in the SPG group was significantly longer than in the control group. However, there was no significant difference in the survival rate of patients with Stage III cancer between the SPG-dosed and control groups.
为评估抗肿瘤多糖裂褶菌多糖（SPG）的临床效果，对220例同时接受放疗的II期或III期宫颈癌患者进行了一项随机研究。SPG对两个阶段的患者均有显著的肿瘤缩小作用。与对照组相比，II期癌症患者中服用SPG的患者复发时间更长。SPG组和对照组的III期癌症患者复发时间无显著差异。比较48个月生存曲线时，SPG组II期癌症患者的生存时间显著长于对照组。然而，服用SPG组和对照组的III期癌症患者生存率无显著差异。
